Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption.
Artikel i vetenskaplig tidskrift, 2004

OBJECTIVE: The objective was to investigate the effects of 3 years of growth hormone (GH) replacement therapy in GH deficient (GHD) patients in Sweden. DESIGN AND PATIENTS: An open label study in 237 adults with GHD (116 men and 121 women), consecutively enrolled in KIMS (Pfizer's international metabolic database) in Sweden. MEASUREMENTS: QoL and healthcare consumption were determined using questionnaires [QoL-assessment of GHD in Adults (QoL-AGHDA), the psychological general well-being (PGWB) index and the patient life situation form (PLSF)]. RESULTS: The mean starting dose of GH was 0.13 mg/day and the mean maintenance dose was 0.37 mg/day. The mean insulin-like growth factor I (IGF-I) SD score increased from -1.92 at baseline to 0.38 after 3 years. There was a sustained increase in QoL as measured by the QoL-AGHDA and PGWB questionnaires. The number of doctor visits and the number of days in hospital were reduced after 3 years of GH replacement. The number of days of sickleave decreased during the first 2 years of treatment, but returned towards baseline values after 3 years. Leisure-time physical activity and satisfaction with physical activity increased. CONCLUSION: Three years of GH replacement therapy induced a sustained improvement in QoL. Healthcare consumption was reduced, although the reduction in the number of days of sickleave was not statistically significant after 3 years of treatment.

metabolism

therapeutic use

Delivery of Health Care

drug therapy

Adult

Human Growth Hormone

analysis

Insulin-Like Growth Factor I

Questionnaires

adverse effects

utilization

Aged

Female

Sweden

Hypopituitarism

Quality of Life

Humans

Hormone Replacement Therapy

adverse effects

deficiency

Male

Time Factors

Syndrome

Författare

Johan Svensson

Göteborgs universitet

Anders Mattsson

Thord Rosén

Göteborgs universitet

Lena Wirén

Göteborgs universitet

Gudmundur Johannsson

Göteborgs universitet

Bengt-Åke Bengtsson

Göteborgs universitet

Maria Koltowska Häggström

Growth Hormone and IGF Research

1096-6374 (ISSN)

Vol. 14 3 207-15

Ämneskategorier

MEDICIN OCH HÄLSOVETENSKAP

DOI

10.1016/j.ghir.2003.12.001

PubMed

15125882